# Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application:

Claims 1-6 (canceled).

7. (Currently amended) <u>A</u> The pharmaceutical composition of claim 1, comprising a compound having the following formula (I):

wherein:

## (a) X is CH or N;

- (b) R<sub>1</sub> is hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;
- (c) R2 is hydrogen, alkyl, aralkyl, aryl, or heteroaryl;
- (d) R<sub>2</sub> is hydrogen unless R<sub>2</sub> is methyl, in which case R<sub>2</sub> is also methyl;
- (e) R<sub>3</sub> has the following formula (III):

wherein:

 (i) R<sub>a</sub> is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;

(ii) R<sub>3</sub> is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;

(iii) R<sub>6</sub> is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;

(iv)  $R_4$  and  $R_5$  when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(y) wherein R<sub>5</sub> and R<sub>6</sub> when taken together are selected from the group consisting of a methylenedioxy group and an ethylenedioxy group;

(f) L is selected from the group consisting of  $-(CH_2)_{m-1}$ , where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl mojety of the formula (IV):

wherein:

(i) n is 0, 1 or 2;

(ii) R7 and R8 are hydrogen, methyl or ethyl;

(iii) R9 and R9' are both hydrogen, methyl or ethyl;

(iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9' are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

8. (Currently amended) <u>A The pharmaceutical composition of elaim 1, comprising a compound having the following formula (I):</u>

wherein:

(a) X is CH or N;

(b)  $R_1$  is hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl;

- (c) R2 is hydrogen, alkyl, aralkyl, aryl, or heteroaryl;
- (d) R<sub>2</sub> is hydrogen unless R<sub>2</sub> is methyl, in which case R<sub>2</sub> is also methyl;

### (e) R<sub>3</sub> has the following formula (III):

### wherein:

- (i) R<sub>4</sub> is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;
- (ii) R<sub>2</sub> is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;
- (iii) R6 is alkyl, halo, alkoxy, perfluoroalkyl, perfluoroalkoxy, or nitro;
- (iv)  $R_4$  and  $R_5$  when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms:
- (y) Rs and R6 when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(f) wherein L is an alkyl substituted hydrocarbyl moiety of formula (IV):

wherein:

(i) n is 0, 1 or 2;

(ii) R7 and R8 are hydrogen, methyl or ethyl;

(iii) R9 and R9' are both hydrogen, methyl or ethyl;

(iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9' are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl.

and pharmaceutically acceptable salts and esters thereof.

Claims 9-18 (canceled).

(Currently amended) <u>A The pharmaceutical composition of claim 1, wherein the comprising a compound is selected from the group consisting of:</u>

1-{4-[4-(4-Fluorophenyl)piperazin-1-vl]butyl}-1,5,6,7-tetrahydroindol-4-one;

1-{3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one;

1-{4-[4-(2,4-Dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;

1-{4-[4-(3-Chloro-4-fluorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one;

1-{4-[4-(4-Bromophenyl)piperazine-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one; and

1-{4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one, and pharmaceutically acceptable salts and esters thereof.

 (Previously presented) The pharmaceutical composition of claim 19, wherein the compound is 1-(4-[4-(3,4-dichlorophenyl)piperazin-1-yl]butyl}-1,5,6,7-tetrahydroindol-4-one.

### Claim 21 (canceled).

22. (Currently amended) <u>A The pharmaceutical composition of claim 5, comprising a compound having the following formula (I):</u>

wherein:

### (a) X is CH or N:

(b) R<sub>1</sub> is hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, aralkenyl, heteroaralkenyl, aryl, or heteroaryl:

(c) R2 is hydrogen, alkyl, aralkyl, aryl, or heteroaryl;

(d)  $R_2$  is hydrogen unless  $R_2$  is methyl, in which case  $R_2$  is also methyl;

### (e) R<sub>3</sub> has the following formula (III):

#### wherein:

(i) R<sub>4</sub> is hydrogen, alkyl, halo, hydroxy, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, or hydroxymethyl;

(iii) Re is hydrogen, alkyl, halo, alkoxy, cyano, nitro, perfluoroalkyl, perfluoroalkoxy, amino, aminocarbonyl, aminosulfonyl, or hydroxymethyl;

### (iii) wherein R6 is halo;

(iv)  $R_4$  and  $R_5$  when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms:

(v) R<sub>s</sub> and R<sub>6</sub> when taken together can form a 5 or 6 membered ring and can contain one or more heteroatoms;

(f) L is selected from the group consisting of –(CH<sub>2</sub>)<sub>m</sub>, where m is an integer from 1 to 6, and an alkyl substituted hydrocarbyl mojety of the formula (IV):

wherein:

(i) n is 0, 1 or 2;

(ii) R7 and R8 are hydrogen, methyl or ethyl;

(iii) R9 and R9' are both hydrogen, methyl or ethyl;

(iv) if n is 1 and R7 or R8 is methyl or ethyl, then R9 and R9' are hydrogen;

(v) if n is 1 and R7 and R8 are hydrogen, then R9 and R9' are methyl or ethyl; and

(vi) if n is 2, then R9 and R9' are hydrogen and one or both of R7 and R8 are methyl or ethyl,

and pharmaceutically acceptable salts and esters thereof.

23. (Previously presented) The pharmaceutical composition of claim 22, wherein  $R_5$  and  $R_6$  are halo.

Claims 24-25 (canceled).